drug · protein
lutetium Lu 177 dotatate
Marketedupdated 6mo agoby Advanced Accelerator Applications SA🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neuroendocrine neoplasm and neuroendocrine carcinoma and 7 investigational indications.
targets
Somatostatin receptor
all catalysts(0)
nothing on the calendar yet
Trials studying lutetium Lu 177 dotatate
- phase2177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
- —Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
- phase3Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- —Post-Authorization Long-Term Safety Study of LUTATHERA
- —LUTATHERA Injection General Use Result Survey
- phase1Lutathera and ASTX727 in Neuroendocrine Tumours
- phase1Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
- phase2Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 23, 2027
154 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Jan 25, 2039patentUS 10596276*PED
- Jan 25, 2039patentUS 10596278*PED
- Jan 25, 2039patentUS 11904027*PED
- Jan 25, 2039patentUS 12144873*PED
- Jan 25, 2039patentUS 12151003*PED
- Jan 25, 2039patentUS 12161732*PED
- Jan 25, 2039patentUS 12168063*PED
- Jan 25, 2039patentUS 12415003*PED
- Jan 25, 2039patentUS 12491272*PED
- Jul 25, 2038formulationUS 10596276
- Jul 25, 2038formulationUS 10596278
- Jul 25, 2038formulationUS 11904027
- Jul 25, 2038method-of-use (U-4036)US 12144873
- Jul 25, 2038formulationUS 12151003
- Jul 25, 2038formulationUS 12161732
- Jul 25, 2038formulationUS 12168063
- Jul 25, 2038method-of-use (U-4036)US 12415003
- Jul 25, 2038method-of-use (U-4036)US 12491272
FDA exclusivities (4)
- Oct 23, 2031PEDPediatric (6mo bonus)4.9y
- Apr 23, 2031ODE-479Orphan Drug (7y)4.4y
- Oct 23, 2027PEDPediatric (6mo bonus)337d
- Apr 23, 2027NPPNew Product (3y)154d
News(10)
- PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMOLess than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.biospace · 6d ago
- BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma winThe centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.biospace · 1mo ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 1mo ago
- Curium prices generic radioligand at 5% discount to Novartis' LutatheraCurium has set the list price for Bexlutry, its radiosimilar to Novartis’ Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant’s drug. Challenging Novartis in th…endpoints · 1mo ago
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- 3 steps for taking on Novartis in radiopharma: Curium up firstTo successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.biospace · 1mo ago
- Novartis bets up to $900M for radioligand therapy from China’s BoomRayNovartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.biospace · 1mo ago
- Novartis secures new radioligand in $900M deal as competition strengthensAs an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.fiercebiotech · 1mo ago
- Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapiesDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 1mo ago
- Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecastsDeals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.biospace · 1mo ago
Data sources
last refreshed 50m ago
Found something off?
comments(0)
5-min edit window · permanent after that